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ABSTRACT Acyclovir [92-hydroxyethoxymethyl)guanineJ
triphosphate inhibits Epstein-Barr virus (EBV)associated DNA
polymerase (DNA nucleotidyltransferase; EC 2.7.7.7) to a greater
extent than it inhibits host a and jB DNA polymerases. The af-
finity of the compound for viral polymerase is 100-fold higher
than for a-polymerase. The extent of inhibition is dependent
upon the base composition of the template-primer. The inhibi-
tion is prevented by increasing concentrations of deoxyguano-
sine triphosphate. The EBV-associated DNA polymerase reac-
tion in the presence of the inhibitor, although depressed, pro-
ceeds at a linear rate over a long period of time. In contrast, the
reaction of Escherichia coli DNA polymerase I in the presence
of 2',3'-dideoxythymidine 5'-triphosphate, a DNA chain termi-
nator, levels off after initial linearity. Preincubation of acyclovir
triphosphate with DNA and enzyme does not increase its in-
hibitory activity. The virus-producing cell line P3HR-1 consis-
tently shows reduced viral genome numbers and viral capsid
antigen on prolonged exposure to acyclovir. The number of EBV
genomes returns to the control level when the cells are grown
in drug-free medium. The results suggest that a competitive
mechanism is the major mode of acyclovir inhibition of EBV
replication.
Selective prevention of virus replication can be attained by
compounds that inactivate the novel enzymes necessary for
virus growth. Virus-specific DNA polymerase (deoxynucleoside
triphosphate:DNA nucleotidyltransferase, EC 2.7.7.7) is one
of the target enzymes most suitable for this purpose (1-3).
Several nucleoside analogs inhibit virus replication by affecting
this enzyme (4-9). Acyclovir [ACV; 9-(2-hydroxyethoxy-
methyl)guanine] is one of a class of antiviral compounds re-
cently shown to be effective in a variety of herpesvirus infec-
tions in vitro and in animal models (10). In both herpes simplex
virus (HSV) type I and type II systems the drug is highly ef-
fective with an ED50 (effective dose required for 50% inhibi-
tion) of 0.1-0.2 AM without adverse effect on the host cells.
Studies on the mechanism of action of this compound in HSV
systems have shown that the drug is phosphorylated by the
virus-specified thymidine kinase to its monophosphate form,
which is subsequently converted to triphosphate by the host
enzyme systems (11, 12). The triphosphorylated form of this
compound inhibits viral DNA synthesis by inhibiting viral DNA
polymerase by competing with dGTP (13). Results have been
presented to suggest that the drug is incorporated into HSV
DNA chains and thus terminates viral DNA synthesis (13).
Recent genetic experiments also suggest that at least two virally
coded functions, namely, virus-specific thymidine kinase and
DNA polymerase, are responsible for the action of acyclovir in
HSV-infected cells (14, 15).
The compound is also effective in inhibiting Epstein-Barr
virus (EBV) replication at drug-dosage levels (6-7 ,uM) that are
essentially nontoxic to host cells (16). In contrast, there is little
if any effect on human cytomegalovirus at drug concentrations
up to 50MM (17). This intermediate sensitivity of EBV to this
drug with respect to HSV and human cytomegalovirus
prompted us to look into its effect on EBV DNA replication.
The present studies show that acyclovir triphosphate inhibits
EBV-associated DNA polymerase to a much greater extent than
it inhibits host a- and /3-polymerases. The triphosphorylated
form of the drug behaves as a classical competitive inhibitor of
EBV DNA polymerase with respect to dGTP. The concept that
the action of this drug is reversible is further supported by the
fact that the virus-producing cells (P3HR-1) exposed to the drug
over a long period of time show lowered levels of viral capsid
antigen (VCA) and viral genome numbers that return to control
levels with the removal of the drug. These observations, coupled
with the apparent inefficient phosphorylation of ACV in
EBV-infected cells (unpublished results), in contrast to the
striking and selective phosphorylation in HSV-infected cells
(11, 12), lead us to propose that the high sensitivity of EBV-
associated DNA polymerase towards ACV triphosphate ac-
counts for the inhibition of EBV replication. In this case a small
amount of phosphorylated drug, phosphorylated perhaps by
host thymidine or purine nucleoside kinases, is sufficient to
inhibit EBV.
MATERIALS AND METHODS
Cells. The Burkitt lymphoma-derived cell line P3HR-1 (gift
of E. Kieff) (18), was maintained between 5 X 10( and 106 cells
per ml in RPMI 1640 medium containing 10% heat-inactivated
fetal calf serum supplemented with penicillin at 100 interna-
tional units/ml and streptomycin at 100 ,ug/ml.
Chemicals. 12-O-Tetradecanoylphorbol 13-acetate was from
Sigma. Synthetic deoxyhomopolymer-oligomer templates,
unlabeled deoxynucleoside triphosphates and 2',3'-dideoxy-
thymidine 5'-triphosphate (ddTTP) were obtained from P-L
Biochemicals. 3H-Labeled deoxynucleoside triphosphates were
the products of New England Nuclear. ACV and its triphos-
phorylated derivative were generously provided by G. Elion
of the Burroughs Wellcome (Research Triangle Park, NC).
Escherichia coli DNA polymerase I purified by the method of
Jovin et al. (19) was the gift of Sankar Mitra of Oak Ridge
National Laboratory, Oak Ridge, TN.
Purification of DNA Polymerases. EBV-associated DNA
polymerase and other host polymerases were purified according
to the method of Datta et al. (20). Nuclear extract from P3HR-1
cells treated with tetradecanoylphorbol acetate was used for
enzyme purification. The purified virus-associated enzyme
could be differentiated from cellular polymerases by its acti-
vation with salt and its degree of sensitivity to N-ethylmalei-
mide and phosphonoacetic acid. The enzyme shows maximal
The publication costs of this article were defrayed in part by page
charge payment. Thisarticle must therefore be hereby marked "ad-
vertisement" in accordance with 18 U. S. C. §1734 solely to indicate
this fact.
5163
Abbreviations: EBV, Epstein-Barr virus; HSV, herpes simplex virus;
ddTTP, 2',3'-dideoxythymidine 5'-triphosphate; EA, early antigen;
VCA, viral capsid antigen; ACV, acyclovir [9-(2-hydroxyethoxy-
methyl)guanine].
Proc. Natl. Acad. Sci. USA 77 (1980)
activity for copying deoxyoligomer-homopolymer templates,
but fails to copy poly(rA)-(dT)jo and (dT)1,o which shows ab-
sence of y DNA polymerase, reverse transcriptase, and terminal
deoxynucleotidyltransferase (20-23).
Immunofluorescence Assay. EBV early antigen (EA) and
VCA antigen were determined from cell smears according to
Henle and Henle (24). EA-/VCA+ (Kampala) and EA+/VCA+
(Ghana) sera were used for these determinations. Sera were the
generous gift of W. Henle.
DNA Polymerase Assay. DNA polymerase was assayed as
follows: The reaction mixture (100 Al) contained 25 mM Hepes
(pH 8.0), 10mM MgCI2, 2 mM dithiothreitol, 0.2 mM EDTA,
dialyzed bovine serum albumin at 20 ,ug/ml, 100mM ammo-
nium sulfate, 10,g of activated calf thymus DNA, 20AM
3H-labeled deoxynucleoside triphosphates (either dTTP or
dGTP as mentioned, specific activity 1000 cpm/pmol), 20AM
dATP, dGTP (or dTTP), and dCTP, and the amount of enzyme
required to keep the reaction in the linear range. For a, fl, and
E. coli DNA polymerase I assays salt was omitted from the re-
action mixture. The reaction was carried out at 370C for 30 min
qr as indicated, after which it was stopped with 20 ul of 0.1 M
EDTA. Aliquots (60 Al) were taken and soaked into a DE-81
filter paper (Whatman). The papers were washed with 5%
Na2HPO4 and alcohol as described by Lindell et al. (25), and
the radioactivity was determined in toluene-based solvent. At
370C the reaction is linear for at least 1 hr.
Determination of Viral Genome Number by cRNA-DNA
Hybridization. Cellular DNAs from mock-treated and drug-
treated P3HR-1 cells were prepared as described (26). cRNA-
DNA hybridization, with virus-specific [3H]RNA as a probe,
was conducted as described (16).
RESULTS
Effect of ACV Triphosphate on Viral and Cellular DNA
Polyperases. Results presented in Fig. 1 show the effect of
ACV triphosphate on viral and cellular DNA polymerases. With
activated calf thymus DNA as template (Fig. 1A) the EBV-
associated polymerase is strongly inhibited by increasing con-
centrations of ACV triphosphate. At 100MuM little residual ac-
tivity is detected, whereas a and : polymerases retained 50%
and 90% of the residual activity, respectively, at the same
concentration. With the omission of dGTP as one of the sub-
strates, the extent of inhibition is reduced at comparable con-
centrations of the drug (Fig. 1B). To decide whether the extent
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FIG. 1. Effect ofACV triphosphate on different DNA polymerase
activities: EBV-associated DNA polymerase (0), a DNA polymerase
(0), and P DNA polymerase (-). The methods of assay are as de-
scribed in Materials and Methods except that in experiments shown
in B dGTP was omitted from the reaction, and in C poly(dA)-(dT)h128




FIG. 2. Inhibition ofEBV and a-DNA polymerase activities by
ACV triphosphate as a function ofdGTP concentration. The results
are displayed in Lineweaver-Burk (Right) and Dixon (Left) plots.
Reaction velocities v are expressed as counts of dTMP (specific ac-
tivity, 1000 cpm/pmol) incorporated per 30 min per mg of protein.
(A) EBV polymerase. For Lineweaver-Burk plots, concentrations of
ACV triphosphate were 0 (U), 1 (0), 2.5 (A), and 6 (-) AM. In the
Dixon plots, concentrations ofdGTP were 2 (0), 4 (&), and 8 (D) AM.
(B) a-Polymerase. For Lineweaver-Burk plots, concentrations of
ACV triphosphate were 0 (-) and 2.5 (0) uM. In the Dixon plots,
concentrations of dGTP were 2 (0) and 4 (0) MM.
we also studied the effect of this triphosphorylated compound
on synthetic poly(dA).(dT)12s18 template-primer. The extent
of inhibition is much less with this template. Our results agree
with the findings of Furman et al. (13) with HSV-I-specified
DNA polymerase and point to the fact that ACV triphosphate
competes more efficiently with dGTP than with other deoxy-
nucleoside triphosphates.
Mode of Inhibition by ACV Triphosphate and Determi-
nation of Inhibition Constant(s). Although the observations
above indicated differential sensitivity of different polymerases
towards ACV triphosphate, the results disclosed nothing of the
nature of the inhibition. The results in Fig. 2 in the form of
Lineweaver-Burk and Dixon plots and Table 1 demonstrate
that the analog behaves as a classical competitive inhibitor of
dGTP with both EBV-specified and a-polymerases. The af-
finity of EBV-associated polymerase (Fig. 2A) for the com-
petitive inhibitor (Ki = 0.015 + 0.002 AsM) is almost 100 times
greater than that of a-polymerase (Ki = 1.5 I 0.05 ,M) (Table
1). Moreover, the differential inhibitory potency of the analog
for the two polymerases is further enhanced by the fact that
their values of apparent Km for the competitive substrate,
dGTP, differ in a precisely reciprocal manner (Table 1).
Kinetics ofDNA Polymerase Reaction in the Presence of
Inhibitors: Competition Versus Chain Termination. Furman
et al. (13) have evidence that ACV triphosphate is not only a
competitive inhibitor of HSV-I-specified DNA polymerase but
also a substrate for this enzyme. Incorporation of ACV mono-
Table 1. Apparent kinetic constants for different
DNA polymerases
Apparent
Apparent Ki for ACV
Km for dGTP, triphosphate,
DNA polymerase OM AM
Lymphoblastoid cell a 0.18 + 0.02 1.5 0.05
EBV 0.025 + 0.005 0.015 I 0.002
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FIG. 3. Kinetics of EBV DNA polymerase (A) and E. coli DNA
polymerase I (B) reactions in presence of ACV triphosphate and
ddTTP, respectively. The reactions were carried out as described in
Materials and Methods except that the following were used as sub-
strates. In A, EBV DNA polymerase: four dNTPs (A), three dNTPs
without dGTP (o), and three dNTPs plus ACV triphosphate (10 jM)
instead of dGTP (-); in B, for E. coli DNA polymerase I: four dNTPs
(ti), three dNTPs but without dTTP (-), and three dNTPs plus
ddTTP (200 ,uM) instead of dTTP (0).
phosphate resulted in reduction in the rate of HSV-I-specified
DNA polymerase reaction in vitro with activated calf thymus
DNA as template-primer. This result led to the conclusion that
incorporation of ACV monophosphate into the 3' termini of
DNA leads to chain termination, a basis for inhibition of virus
replication (10). In order to determine whether the same
mechanism is operative in EBV DNA polymerase-mediated
reactions, we measured the kinetics of reaction in the presence
and absence of ACV triphosphate.
The results in Fig. 3A show that the EBV-specified DNA
polymerase reaction, although inhibited, proceeded linearly
over a long period of time when ACV triphosphate was sub-
stituted for dGTP as one of the substrates. Such kinetics of re-
action are possible only if the effect of the drug is competitive
with respect to the substrate. In contrast, the velocity of the
reaction of E. coli DNA polymerase I in the presence of ddTTP,
a well-characterized chain terminator (27), rapidly fell after
Table 2. Effect of preincubation of EBV-associated DNA
polymerase and E. coli DNA polymerase I with
ACV triphosphate and ddTTP
DNA Residual
poly- Conc., activity,
merase Experiment Inhibitor ,uM %
E. coli I Control None 100
No preincubation ddTTP 200 83 + 5
Preincubation ddTTP 200 33 + 3
EBV Control None 100
No preincubation ACV triphosphate 10 40 + 3
Preincubation ACV triphosphate 10 42 + 2
The assay conditions were the same as described in Materials and
Methods. For the EBV DNA polymerase preincubation experiment,
DNA, dATP, dCTP, d'TPP (20AM each), ACV triphosphate (10 ,uM),
and enzyme were preincubated for 30 min at 37°C. The reaction was
then followed for another 30 min after addition of [3H]dGTP (1000
cpm/pmol) at a final concentration of 20 ,uM. For the E. coli poly-
merase I preincubation experiment, DNA, dATP, dCTP, dGTP (20
jM each), ddTTP (200 AM), and enzyme were preincubated for 30
min at 37°C. The reaction was then followed for another 30 min after
addition of [3H]dTTP (1000 cpm/pmol) at a final concentration of
20 ,uM. For the rest of the experiments the same sequence of additions
was followed but without preincubation. ± indicates variation in five
experiments.
Table 3. Determination ofEBV genome number
EBV genome
equivalents VCA,
Culture* Days per cellt %
Mock-treated P3HR-1 240 10
ACV-treated P3HR-1 7 14 <0.05
ACV-treated P3HR-1 154 18 ND
ACV-removed P3HR-1 154 + 40 323 10
ND, not determined.
* P3HR-1 cells were mock-treated or treated for various lengths of time
with 100 ,gM ACV. ACV was removed from one culture after 154
days; cells were pelleted and suspended in fresh medium lacking
ACV and maintained for 40 days.
t cRNA-DNA hybridization used to quantitate EBV DNA was con-
ducted as described in Materials and Methods. Average hybrid-
ization values were determined for duplicate DNA filters, each
standardized to 50 /ag of DNA per filter. Counts per min bound by
calf thymus and HEP-2 human carcinoma cell DNA were subtracted
as background. Genome number is based on Raji = 50-60 EBV ge-
nome equivalents per cell (28).
the first few minutes of linearity (Fig. 3B). Our unpublished
results also show that when the kinetics of reaction is followed
with EBV DNA polymerase in the presence of ddTTP, a linear
but depressed reaction is obtained over time. Thus, the differ-
ences in the kinetics of reaction between EBV-specified DNA
polymerase and E. coli DNA polymerase I in the presence of
ACV triphosphate and ddTTP, respectively, point to a different
mode of inhibition of DNA synthesis by the two inhibitors with
the respective enzymes.
Effect of Preincubation. Atkinson et al. (27) demonstrated
that the chain terminator ddTTP causes nondissociable binding
of E. coli DNA polymerase I to the primer end blocked with
2',3'-dideoxythymidine 5'-monophosphate (ddTMP). To as-
certain whether such binding also occurs in the case of ACV
triphosphate inhibition of EBV DNA polymerase, the effect
of a prior incubation of polymerase with activated calf thymus
DNA, dATP, dCTP, dTTP, and ACV triphosphate on the rate
of subsequent polymerization was studied. As shown in Table
2, such a prior incubation does not enhance the inhibitory effect
of ACV triphosphate. In contrast, the identical preincubation
experiment with E. coli DNA polymerase I, calf thymus DNA,
dATP, dCTP, dGTP, and ddTTP shows an enhanced inhibitory
activity.
Determination of Viral Genome Number in the Presence
and After the Removal of the Drug. Table 3 shows the effect
of ACV on viral DNA synthesis in the virus-producing P3HR-1
cell line. As determined by EBV cRNA-DNA membrane hy-
bridization, the number of EBV genomes per cell in the pro-
ducer cell line decreased drastically with exposure to ACV. The
reduction in viral genome number reached a steady level on
exposure of the cells to ACV for 7 days, after which further
exposure did not lead to any more reduction. This result was
confirmed by exposing the cells to the drug for 154 days.
Concomitant with the reduction of viral genome number, VCA
also decreased proportionally in the cells. However, when the
ACV-exposed cells were grown again in drug-free medium, the
viral genome number and VCA returned to control levels.
DISCUSSION
In this communication it is shown that EBV DNA polymerase
is extremely sensitive to ACV triphosphate and that the sensi-
tivity of this enzyme to the drug is greater than that of the host
polymerase (Fig. 1). The inhibition by ACV triphosphate of
both viral and cellular polymerases is dependent on the base
composition of the template-primer. Greater inhibition is
observed with activated calf thymus DNA, whereas use of
Biochemistry: Datta et al.
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poly(dA)-(dT)12i8 as template-primer produces much less in-
hibition. Thus the template specificity suggests that ACV tri-
phosphate competes with dGTP (13). The competitive nature
of the inhibition is also evident from the Lineweaver-Burk and
Dixon plots (Fig. 2). The specific inhibition of viral DNA syn-
thesis without much effect on host DNA synthesis (16) can be
explained by the fact that the apparent Ki (0.015 + 0.002 ,uM)
of ACV triphosphate for EBV polymerase is approximately lloo
that of host a-polymerase (1.5 + 0.05 ,uM) (Table 1). In addi-
tion, unpublished results from this laboratory show that the
concentration of ACV triphosphate formed within Raji cells
superinfected with EBV is 2-5 times higher than the apparent
Ki of ACV triphosphate for EBV polymerase, but much lower
than the K; for host polymerases. Thus, a higher affinity of ACV
triphosphate towards EBV polymerase in comparison with
HSV-I-specified polymerases (13) accounts for the fact that, in
spite of inability to detect EBV-specific thymidine kinase
(unpublished results; Y.-C. Cheng, personal communication)
and apparent inefficient phosphorylation of ACV, the drug is
effective in EBV system.
The inhibition of the activity of DNA polymerase by ACV
triphosphate can be explained by two possible mechanisms.
First, ACV triphosphate causes a nondissociable binding of EBV
DNA polymerase to the primer end blocked with ACV mono-
phosphate, and the chain cannot be extended further because
of unavailability of the free 3'-OH group of the sugar moiety.
This mechanism of inhibition has been suggested in the inhi-
bition of HSV-I-specified DNA polymerase by the drug (13).
This mode of inhibition is identical to the proposed mechanism
by Atkinson et al. (27) for ddTTP and E. coli DNA polymerase
I. Second, the viral DNA polymerase is inhibited competitively
by a lower concentration of ACV triphosphate compared with
cellular polymerases so that the drug inhibits EBV DNA syn-
thesis much more strongly than host DNA synthesis. However,
of the two possible mechanisms of inhibition our results are
consistent with the latter one because of the following experi-
mental facts: (i) The inhibition could be reversed in vitro by
the addition of excess dGTP; (ii) the extent of inhibition is less
when dGTP is omitted from the DNA polymerase reaction
mixture; (iii) the linear inhibition kinetics of DNA polymerase
reaction in the presence of the inhibitor over a long period of
time; (iv) the irreversible binding of EBV DNA polymerase to
DNA chains terminated with ACV monophosphate residue is
ruled out by the, observation that preincubation of enzyme,
deoxynucleoside triphosphates, ACV triphosphate, and DNA
did not lead to an increase in the inhibitory activity; and lastly
(v) virus-producing cell lines when exposed to ACV show
marked reduction of viral genome numbers, which recover to
control levels with the removal of the drug from the growth
medium. Therefore, inhibition of EBV DNA polymerase ac-
tivity seems to be the major cause of inhibition of EBV repli-
cation, and chain termination after incorporation, if it occurs,
must take place at extremely low frequency. The phenomenon
of chain termination by a particular nucleoside analog is not
universal. ddTTP, which is a well-characterized chain termi-
nator in reactions mediated byE. coli DNA polymerase I (27)
and reverse transcriptase (29, 30), acts as a purely competitive
inhibitor in the case of eukaryotic a and 3 DNA polymerases
(31). So we infer that, apart from structural features of a par-
ticular nucleoside analog, te active sites of the enzymes might
play some role in determining the mode of action.
The findings described in this paper will allow further use
of ACV triphosphate as a tool for identification of different
DNA polymerases and also for studies of the mechanism of
DNA synthesis in vivo in virus-infected cells. In addition, the
drug might prove to be useful in treatment of EBV-associated
diseases and other herpetic infections.
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